Modality
Cell Therapy
MOA
PI3Ki
Target
SOS1
Pathway
Apoptosis
CRCPTSD
Development Pipeline
Preclinical
~Nov 2014
→ ~Feb 2016
Phase 1
~May 2016
→ ~Aug 2017
Phase 2
Nov 2017
→ Oct 2029
Phase 2Current
NCT08847469
2,307 pts·PTSD
2021-02→2027-10·Active
NCT08201173
263 pts·CRC
2017-11→2029-10·Recruiting
2,570 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-10-091.5y awayPh3 Readout· PTSD
2029-10-113.5y awayPh3 Readout· CRC
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P2/3
Recruit…
P2/3
Active
Catalysts
Ph3 Readout
2027-10-09 · 1.5y away
PTSD
Ph3 Readout
2029-10-11 · 3.5y away
CRC
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08847469 | Phase 2/3 | PTSD | Active | 2307 | CfB |
| NCT08201173 | Phase 2/3 | CRC | Recruiting | 263 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 |